Fox Run Management L.L.C. bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,591 shares of the medical instruments supplier's stock, valued at approximately $712,000.
A number of other hedge funds also recently bought and sold shares of ICUI. Arizona State Retirement System raised its holdings in ICU Medical by 1.0% during the fourth quarter. Arizona State Retirement System now owns 6,730 shares of the medical instruments supplier's stock worth $1,044,000 after purchasing an additional 65 shares in the last quarter. Equitable Trust Co. raised its stake in ICU Medical by 1.6% during the 4th quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier's stock worth $822,000 after acquiring an additional 84 shares in the last quarter. Gagnon Securities LLC raised its stake in ICU Medical by 0.5% during the 4th quarter. Gagnon Securities LLC now owns 28,881 shares of the medical instruments supplier's stock worth $4,481,000 after acquiring an additional 137 shares in the last quarter. Wealthspire Advisors LLC lifted its position in ICU Medical by 6.4% in the fourth quarter. Wealthspire Advisors LLC now owns 2,660 shares of the medical instruments supplier's stock valued at $413,000 after acquiring an additional 160 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in ICU Medical by 1.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 12,370 shares of the medical instruments supplier's stock valued at $1,919,000 after acquiring an additional 191 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.
Insider Buying and Selling at ICU Medical
In related news, CEO Vivek Jain sold 1,373 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at $16,262,119.64. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.70% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the company. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price on the stock in a research report on Wednesday, December 11th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Tuesday, March 18th. Finally, Raymond James set a $97.00 target price on shares of ICU Medical in a research report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $168.67.
Check Out Our Latest Research Report on ICUI
ICU Medical Stock Performance
Shares of NASDAQ ICUI traded up $0.06 during midday trading on Tuesday, reaching $149.88. 238,271 shares of the company were exchanged, compared to its average volume of 256,802. The stock has a fifty day simple moving average of $155.69 and a 200 day simple moving average of $164.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.67 billion, a P/E ratio of -32.80 and a beta of 0.73. ICU Medical, Inc. has a 1 year low of $93.36 and a 1 year high of $196.26.
ICU Medical Profile
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Further Reading
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
